Letermovir Non-inferior to Valganciclovir for CMV Prophylaxis, With Lower Leukopenia Rates
ISN-ACT Global Trials Focus Subgroup member Maria Chiara Pelle summarizes the design and outcomes of one of the ISN-ACT Global Trials Focus’ latest trial selections. Read all the latest global trial selections from the ISN-ACT initiative here. The “trial of the month” is available in several languages. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-risk Kidney Transplant...